Clinical Trial Update: Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Fenretinide Lym-X-Sorb in patients with recurrent or resistant solid tumors or lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Fenretinide Lym-X-Sorb (fenretinide)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED